The Federal Trade Commission said three top pharmacy suppliers made profits of 7,700 percent on a lifesaving hypertension ...
Units of CVS Health Corp., Cigna Group and UnitedHealth Group Inc. charged significantly more than the national average ...
Three major drug middlemen needlessly marked up generic drugs for cancer, HIV, and multiple sclerosis to generate $7.3 ...
The U.S. Federal Trade Commission (FTC) has slammed pharmacy benefit managers (PBMs) owned by UnitedHealth ($UNH), CVS Health ...
On Tuesday, the Federal Trade Commission released its second interim staff report on prescription drug middlemen. The report ...
Regulators published their most detailed findings yet on how some of the nation’s largest companies profited from "excess" ...
The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...
From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.
Investing.com -- Shares of CVS Health Corp (NYSE:CVS), Cigna (NYSE:CI) Group, and UnitedHealth Group Inc (NYSE:UNH) were down around 1% after the Federal Trade Commission (FTC) accused their ...
The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...
FTC report reveals significant markups by top PBMs on specialty drugs, driving $7.3 billion in revenue and raising costs for ...